These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19742428)

  • 21. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2001 Aug; 142(2):204-10. PubMed ID: 11479455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiolabeled tirofiban - a potential radiopharmaceutical for detection of deep venous thrombosis.
    Darkovska-Serafimovska M; Janevik-Ivanovska E; Djorgoski I; Arsova-Sarafinovska Z; Zdravkovska M; Balkanov T; Ugresic N
    Drug Des Devel Ther; 2016; 10():2989-2996. PubMed ID: 27713618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
    Kereiakes DJ; Kleiman NS; Ambrose J; Cohen M; Rodriguez S; Palabrica T; Herrmann HC; Sutton JM; Weaver WD; McKee DB; Fitzpatrick V; Sax FL
    J Am Coll Cardiol; 1996 Mar; 27(3):536-42. PubMed ID: 8606262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
    Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
    Frelinger AL; Furman MI; Barnard MR; Krueger LA; Dae MW; Michelson AD
    Am J Cardiol; 2003 Nov; 92(9):1099-101. PubMed ID: 14583364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
    Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
    J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of thromboelastography in the assessment of platelet function.
    Bowbrick VA; Mikhailidis DP; Stansby G
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):137-42. PubMed ID: 12812383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study.
    Wong P; Harding S; Inglessis I; Choi CJ; Walters D; Chang Y; Gimelli G; Jang IK
    J Thromb Thrombolysis; 2003 Dec; 16(3):163-6. PubMed ID: 15087602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
    J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
    Derhaschnig U; Pachinger C; Jilma B
    Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes.
    Ozkan M; Sag C; Yokusoglu M; Uzun M; Baysan O; Erinc K; Isik E
    Tohoku J Exp Med; 2005 May; 206(1):7-13. PubMed ID: 15802870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
    Lakkis N; Lakiss N; Bobek J; Farmer J
    Catheter Cardiovasc Interv; 2002 Aug; 56(4):474-7. PubMed ID: 12124955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
    Lehne G; Nordal KP; Midtvedt K; Goggin T; Brosstad F
    Thromb Haemost; 1998 Jun; 79(6):1119-25. PubMed ID: 9657435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.